Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript
Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval
Kyverna Therapeutics, Inc. remains a compelling Buy as it advances mivocabtagene autoleucel for autoimmune diseases, targeting first approval in stiff person syndrome. Updated KYSA-8 trial data show all 26 patients remained off chronic immunotherapies at 16 weeks, with 81% mobility improvement, supporting regulatory momentum. Rolling BLA submission for miv-cel is underway, with anticipated completion in late 2026 and potential approval by mid-2027; key phase 2/3 data in myasthenia gravis expected soon.
Kyverna Therapeutics Sinks 13%: Here's Why
Shares of Kyverna Therapeutics (NASDAQ:KYTX) are down almost 13% in Friday afternoon trading, changing hands near $8.60 after opening the session at $9.81.
Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis
Kyverna Therapeutics maintains a "Strong Buy" rating, driven by positive clinical data and upcoming regulatory milestones for miv-cel. Miv-cel achieved statistically significant endpoints in SPS and demonstrated deep, durable responses in gMG, with 100% of patients off chronic immunosuppression at 24 weeks. A BLA filing for SPS is expected in 1H 2026, with additional data from gMG, RA, and PMS programs anticipated as expansion catalysts.
Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.
Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies
Kyverna Therapeutics is upgraded to 'Buy' based on strengthened financials and the potential for commercial launch by the end of 2026. Phase 2 data for mivocabtagene autoleucel shows strong efficacy and favorable safety in autoimmune indications, supporting late-stage advancement. A recent $100 million public offering and an untapped $125 million loan facility extend KYTX's cash runway into 2027, enabling continued pipeline progress.
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript
Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing
Kyverna Therapeutics (KYTX) is upgraded to "Strong Buy" following positive phase 2 data for miv-cel in SPS and MG indications. Company achieved a 46% average improvement in SPS patients in phase 2 KYSA-8 study, surpassing clinical benchmarks of 20% improvement, and plans a BLA filing for SPS in 1H 2026. Phase 3 portion enrollment of phase 2/3 KYSA-6 registrational study for miv-cel in Myasthenia Gravis is set for end of 2025, with updated phase 2 portion data expected in 2026.
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
Kyverna Therapeutics shares jump 23% after a registrational phase II study of miv-cel meets primary and all secondary efficacy goals for treating stiff person syndrome.
Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome
Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome, supporting a bullish outlook. KYTX's Miv-cel achieved significant clinical improvements and eliminated immunotherapy dependence, with a favorable safety profile and no high-grade CRS or ICANS events. A BLA submission for SPS is targeted for 1H26, with FDA approval prospects strengthened by RMAT and Orphan Drug designations.
